common.study.topics.clinical

Esketamine Nasal Spray in Treatment-Resistant Depression

common.study.values.description

A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression

The purpose of this study is to assess the safety and tolerability of esketamine nasal spray in participants with treatment-resistant depression (TRD).

common.study.values.location

participant.ui.study.affiliations-map.online-study.header-virtual

participant.ui.study.affiliations-map.online-study.text

participant.ui.study.affiliations-map.legend.locations participant.ui.study.affiliations-map.legend.selected

common.study.values.methods

Pharmaceutical medication involved common.study.methods.has-drugs-yes
Recruiting patients only common.study.methods.is-healthy-yes

Drug - Esketamine Nasal Spray

Open-Label Induction Phase: Participants will self-administer with esketamine nasal spray twice per week for 4 weeks as a flexible dose regimen (56 milligram [mg] or 84 mg for those < 65 years; 28 mg, 56 mg or 84 mg for those >= 65 years). Participants >= 65 years old will start at a dose of 28 mg on Day 1. Optimization/Maintenance Phase: Participants entering from studies ESKETINTRD3001 (NCT02417064), ESKETINTRD3002 (NCT02418585) or ESKETINTRD3006 (US sites only) will self-administer esketamine ...read more on ClinicalTrials.org

participant.views.study.view.additional

participant.views.study.view.scientific-title

An Open-label Long-term Extension Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression

common.study.values.clinical-trial-id

NCT02782104

participant.views.study.view.id

QbYYAb